Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended March 31, 2025 and 2024 is as follows:

	Three Months Ended March 31, 2025
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	264			1,408		9,754		-				11,426
Cost of revenues (excluding amortization of acquired intangible assets)					209		3,345		-				3,554
Direct expenses		3,257			369		4,747		9,617				17,990
Segment contribution	$	(2,993	)	$	830	$	1,662	$	(9,617	)		$	(10,118	)
Indirect expenses											(a)		368
Loss from operations													(10,486	)
(a) Components of other
Amortization									368
Total other								$	368

	Three Months Ended March 31, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	1,287	$	13,394	$	-			$	14,681
Cost of revenues (excluding amortization of acquired intangible assets)		-			177		1,463		-				1,640
Direct expenses		5,465			416		4,414		9,576				19,871
Segment contribution	$	(5,465	)	$	694	$	7,517		(9,576	)			(6,830	)
Indirect expenses									546		(a)		546
Loss from operations												$	(7,376	)
(a) Components of other
Amortization									546
Total other								$	546